241 related articles for article (PubMed ID: 25376228)
1. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
Pang T; Leach ST; Katz T; Jaffe A; Day AS; Ooi CY
J Gastroenterol Hepatol; 2015 May; 30(5):866-71. PubMed ID: 25376228
[TBL] [Abstract][Full Text] [Related]
2. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old.
Garg M; Leach ST; Pang T; Needham B; Coffey MJ; Katz T; Strachan R; Widger J; Field P; Belessis Y; Chuang S; Day AS; Jaffe A; Ooi CY
J Cyst Fibros; 2018 Jan; 17(1):109-113. PubMed ID: 28754328
[TBL] [Abstract][Full Text] [Related]
3. Intestinal inflammation and impact on growth in children with cystic fibrosis.
Dhaliwal J; Leach S; Katz T; Nahidi L; Pang T; Lee JM; Strachan R; Day AS; Jaffe A; Ooi CY
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):521-6. PubMed ID: 25539196
[TBL] [Abstract][Full Text] [Related]
4. Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?
Ooi CY; Pang T; Leach ST; Katz T; Day AS; Jaffe A
Dig Dis Sci; 2015 Oct; 60(10):2946-52. PubMed ID: 26271615
[TBL] [Abstract][Full Text] [Related]
5. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children.
Garg M; Leach ST; Coffey MJ; Katz T; Strachan R; Pang T; Needham B; Lui K; Ali F; Day AS; Appleton L; Moeeni V; Jaffe A; Ooi CY
J Cyst Fibros; 2017 Sep; 16(5):631-636. PubMed ID: 28416415
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a Cystic Fibrosis Enteropathy.
Adriaanse MP; van der Sande LJ; van den Neucker AM; Menheere PP; Dompeling E; Buurman WA; Vreugdenhil AC
PLoS One; 2015; 10(10):e0138062. PubMed ID: 26484665
[TBL] [Abstract][Full Text] [Related]
8. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.
Czub E; Nowak JK; Moczko J; Mankowski P; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Dev Period Med; 2015; 19(2):167-73. PubMed ID: 26384117
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
10. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis.
Lisowska A; Madry E; Pogorzelski A; Szydłowski J; Radzikowski A; Walkowiak J
Scand J Clin Lab Invest; 2010 Sep; 70(5):322-6. PubMed ID: 20560844
[TBL] [Abstract][Full Text] [Related]
11. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis.
Fallahi G; Motamed F; Yousefi A; Shafieyoun A; Najafi M; Khodadad A; Farhmand F; Ahmadvand A; Rezaei N
Turk J Pediatr; 2013; 55(5):475-8. PubMed ID: 24382526
[TBL] [Abstract][Full Text] [Related]
12. Calprotectin in cystic fibrosis.
Rumman N; Sultan M; El-Chammas K; Goh V; Salzman N; Quintero D; Werlin S
BMC Pediatr; 2014 May; 14():133. PubMed ID: 24885444
[TBL] [Abstract][Full Text] [Related]
13. The intestinal virome in children with cystic fibrosis differs from healthy controls.
Coffey MJ; Low I; Stelzer-Braid S; Wemheuer B; Garg M; Thomas T; Jaffe A; Rawlinson WD; Ooi CY
PLoS One; 2020; 15(5):e0233557. PubMed ID: 32442222
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.
Czub E; Nowak JK; Szaflarska-Poplawska A; Grzybowska-Chlebowczyk U; Landowski P; Moczko J; Adamczak D; Mankowski P; Banasiewicz T; Plawski A; Walkowiak J
Acta Biochim Pol; 2014; 61(1):99-102. PubMed ID: 24649481
[TBL] [Abstract][Full Text] [Related]
15. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
Jeffery J; Lewis SJ; Ayling RM
Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
[TBL] [Abstract][Full Text] [Related]
16. Fecal Calprotectin in Cystic Fibrosis and Its Relation to Disease Parameters: A Longitudinal Analysis for 12 Years.
Ellemunter H; Engelhardt A; Schüller K; Steinkamp G
J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):438-442. PubMed ID: 28207476
[TBL] [Abstract][Full Text] [Related]
17. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis.
Flass T; Tong S; Frank DN; Wagner BD; Robertson CE; Kotter CV; Sokol RJ; Zemanick E; Accurso F; Hoffenberg EJ; Narkewicz MR
PLoS One; 2015; 10(2):e0116967. PubMed ID: 25658710
[TBL] [Abstract][Full Text] [Related]
18. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
[TBL] [Abstract][Full Text] [Related]
19. Severe disease in Cystic Fibrosis and fecal calprotectin levels.
Parisi GF; Papale M; Rotolo N; Aloisio D; Tardino L; Scuderi MG; Di Benedetto V; Nenna R; Midulla F; Leonardi S
Immunobiology; 2017 Mar; 222(3):582-586. PubMed ID: 28012584
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children.
Czub E; Nowak JK; Moczko J; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Sci Rep; 2014 Apr; 4():4769. PubMed ID: 24759699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
